Evidence map›Paper›PMID 39783800›Full record

ArticleBioanalysis2025

Pharmacokinetic analysis using single dilution assays: enhancing precision, reducing errors and increasing throughput.

Saloumeh K Fischer, Xiaome Xu, Hayeun Ji, Bingqing Zhang, Jeongsup Shim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Saloumeh K FischerBioanalytical Sciences (BAS), Genentech Research and Early Development, South San Francisco, CA, USA.
Xiaome XuTechnology Access Program, Alamar Biosciences, Fremont, CA, USA.
Hayeun JiTechnology Access Program, Alamar Biosciences, Fremont, CA, USA.
Bingqing ZhangTechnology Access Program, Alamar Biosciences, Fremont, CA, USA.
Jeongsup ShimBioanalytical Sciences (BAS), Genentech Research and Early Development, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTechnologies such as ELISA, MSD, and Gyrolab have been employed for quantifying protein therapeutics in clinical trials. However, these technologies have limitations with dynamic range often requiring multiple dilution steps, introducing potential errors and variability. RESULTS/METHODOLOGY: A pharmacokinetics assay was successfully developed on the NUcleic acid Linked Immuno-Sandwich Assay (NULISA) platform with a concentration dynamic range exceeding 6 logs. This enabled assessment of all clinical samples across different concentrations with a single dilution, yielding results with good correlation to ELISA and Gyrolab.

conclusionsNULISA technology offers high sensitivity, full automation, and a wide dynamic range, streamlining assay development and optimization, simplifying sample analysis, minimizing errors, and increasing throughput.

Indexed as

High-Throughput Screening AssaysPharmacokineticsEnzyme-Linked Immunosorbent AssayHumansautomationdynamic rangeetrolizumabNULISAPharmacokinetic

Identifiers

PMID39783800
PMCPMC11749389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.